Lipe & Dalton Bristol Myers Squibb CO Transaction History

Lipe & Dalton

$198 Million
Q3 2024

A detailed history of Lipe & Dalton transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lipe & Dalton holds 56,561 shares of BMY stock, worth $3.26 Million. This represents 1.48% of its overall portfolio holdings.

Number of Shares

56,561

Previous 57,151 1.03%

Holding current value

$3.26 Million

Previous $2.37 Million 23.3%

% of portfolio

1.48%

Previous 1.28%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$39.66 - $51.75 $23,399 - $30,532	-590 Reduced 1.03%	56,561 $2.93 Million
Q2 2024 Aug 02, 2024	SELL	$40.25 - $52.99 $61,582 - $81,074	-1,530 Reduced 2.61%	57,151 $2.37 Million
Q1 2024 May 07, 2024	BUY	$47.98 - $54.4 $21,591 - $24,480	450 Added 0.77%	58,681 $3.18 Million
Q4 2023 Jan 30, 2024	SELL	$48.48 - $57.85 $22,785 - $27,189	-470 Reduced 0.8%	58,231 $2.99 Million
Q3 2023 Nov 03, 2023	SELL	$57.89 - $64.73 $10,999 - $12,298	-190 Reduced 0.32%	58,701 $3.41 Million
Q2 2023 Jul 26, 2023	SELL	$63.71 - $70.74 $36,951 - $41,029	-580 Reduced 0.98%	58,891 $3.77 Million
Q1 2023 May 02, 2023	SELL	$65.71 - $74.53 $1.14 Million - $1.29 Million	-17,289 Reduced 22.52%	59,471 $4.12 Million
Q4 2022 Feb 03, 2023	SELL	$68.48 - $81.09 $7,053 - $8,352	-103 Reduced 0.13%	76,760 $5.52 Million
Q3 2022 Nov 07, 2022	BUY	$0.13 - $76.84 $13 - $7,760	101 Added 0.13%	76,863 $5.46 Million
Q2 2022 Aug 01, 2022	SELL	$72.62 - $79.98 $10,820 - $11,917	-149 Reduced 0.19%	76,762 $5.91 Million
Q1 2022 Apr 26, 2022	SELL	$61.48 - $73.72 $32,154 - $38,555	-523 Reduced 0.68%	76,911 $5.62 Million
Q4 2021 Feb 01, 2022	BUY	$53.63 - $62.52 $65,214 - $76,024	1,216 Added 1.6%	77,434 $4.83 Million
Q3 2021 Nov 01, 2021	BUY	$59.17 - $69.31 $261,294 - $306,072	4,416 Added 6.15%	76,218 $4.51 Million
Q2 2021 Aug 02, 2021	BUY	$61.91 - $67.42 $31,697 - $34,519	512 Added 0.72%	71,802 $4.8 Million
Q1 2021 Apr 30, 2021	BUY	$59.34 - $66.74 $4,509 - $5,072	76 Added 0.11%	71,290 $4.5 Million
Q4 2020 Jan 29, 2021	SELL	$57.74 - $65.43 $18,707 - $21,199	-324 Reduced 0.45%	71,214 $4.42 Million
Q3 2020 Oct 30, 2020	SELL	$57.43 - $63.64 $12,806 - $14,191	-223 Reduced 0.31%	71,538 $4.31 Million
Q2 2020 Aug 07, 2020	SELL	$54.82 - $64.09 $70,114 - $81,971	-1,279 Reduced 1.75%	71,761 $4.22 Million
Q1 2020 May 01, 2020	SELL	$46.4 - $67.43 $65,145 - $94,671	-1,404 Reduced 1.89%	73,040 $4.07 Million
Q4 2019 Jan 21, 2020	BUY	$49.21 - $64.19 $180,895 - $235,962	3,676 Added 5.19%	74,444 $4.78 Million
Q3 2019 Nov 07, 2019	SELL	$42.77 - $50.71 $99,568 - $118,052	-2,328 Reduced 3.18%	70,768 $3.59 Million
Q2 2019 Jul 24, 2019	SELL	$44.62 - $49.34 $15,750 - $17,417	-353 Reduced 0.48%	73,096 $3.32 Million
Q1 2019 Apr 30, 2019	SELL	$45.12 - $53.8 $28,380 - $33,840	-629 Reduced 0.85%	73,449 $3.5 Million
Q4 2018 Feb 08, 2019	BUY	$48.76 - $63.23 $368,186 - $477,449	7,551 Added 11.35%	74,078 $3.85 Million
Q3 2018 Nov 05, 2018	SELL	$55.19 - $62.25 $2,704 - $3,050	-49 Reduced 0.07%	66,527 $4.13 Million
Q2 2018 Aug 06, 2018	SELL	$50.53 - $62.98 $58,109 - $72,427	-1,150 Reduced 1.7%	66,576 $3.68 Million
Q1 2018 May 04, 2018	BUY	$59.92 - $68.98 $34,873 - $40,146	582 Added 0.87%	67,726 $4.28 Million
Q4 2017 Feb 13, 2018	SELL	$59.94 - $65.35 $60,239 - $65,676	-1,005 Reduced 1.47%	67,144 $4.12 Million
Q3 2017 Nov 03, 2017	BUY	$55.23 - $63.74 $51,916 - $59,915	940 Added 1.4%	68,149 $4.34 Million
Q2 2017 Aug 08, 2017	BUY	N/A	67,209	67,209 $3.75 Million

Others Institutions Holding BMY

# of Institutions

2,536

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

News

Stay updated on Lipe & Dalton with notifications on news.

Account